The social value of a QALY: raising the bar or barring the raise?

[1]  P. Shackley,et al.  Contingent Valuation in Health Care , 2012 .

[2]  I. Bateman,et al.  Weighting and valuing quality-adjusted life-years using stated preference methods: preliminary results from the Social Value of a QALY Project. , 2010, Health technology assessment.

[3]  Jing Jing Li,et al.  Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. , 2009, JAMA.

[4]  M. Jones-Lee,et al.  Modelling the monetary value of a QALY: a new approach based on UK data. , 2009, Health economics.

[5]  M. Buxton,et al.  Searching for cost effectiveness thresholds in the NHS. , 2009, Health policy.

[6]  J. Sheather.  Confidentiality and sharing health information , 2009, BMJ : British Medical Journal.

[7]  J. Raftery.  Should NICE’s threshold range for cost per QALY be raised? No , 2009, BMJ : British Medical Journal.

[8]  A. Towse.  Should NICE’s threshold range for cost per QALY be raised? Yes , 2009, BMJ : British Medical Journal.

[9]  Anthony V Large.  Paul Garner Large , 2009, BMJ : British Medical Journal.

[10]  N. Rice,et al.  Does health care spending improve health outcomes? Evidence from English programme budgeting data. , 2008, Journal of health economics.

[11]  O. Johansson-Stenman,et al.  Are some lives more valuable? An ethical preferences approach. , 2008, Journal of health economics.

[12]  Andrew M. Jones.  The Elgar Companion to Health Economics , 2007 .

[13]  Karl Claxton,et al.  Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence , 2007, Journal of health services research & policy.

[14]  P. Younger.  The Elgar Companion to Health Economics , 2006 .

[15]  M. Suarez‐Almazor,et al.  Willingness to Pay per Quality-Adjusted Life Year in a Study of Knee Osteoarthritis , 2005, Medical decision making : an international journal of the Society for Medical Decision Making.

[16]  J. Lave,et al.  Willingness to Pay for a Quality-Adjusted Life Year: Implications for Societal Health Care Resource Allocation , 2005, Medical decision making : an international journal of the Society for Medical Decision Making.

[17]  Anthony J Culyer,et al.  National Institute for Clinical Excellence and its value judgments , 2004, BMJ : British Medical Journal.

[18]  David Parkin,et al.  Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. , 2004, Health economics.

[19]  D. Gyrd-Hansen.  Willingness to pay for a QALY , 2003, PharmacoEconomics.

[20]  A. M. James.  Cost-value analysis in health care , 2001 .

[21]  Michael E. Chernew,et al.  Willingness to Pay for a Quality-adjusted Life Year , 2000, Medical decision making : an international journal of the Society for Medical Decision Making.

[22]  J. Pinto-Prades,et al.  Health state after treatment: a reason for discrimination? , 1999, Health economics.

[23]  P. Dolan,et al.  Using the person trade-off approach to examine differences between individual and social values. , 1998, Health economics.

[24]  J. Richardson,et al.  Maximizing health benefits vs egalitarianism: an Australian survey of health issues. , 1995, Social science & medicine.

[25]  Graham Loomes,et al.  VALUING THE PREVENTION OF NON-FATAL ROAD INJURIES: CONTINGENT VALUATION VS. STANDARD GAMBLES , 1995 .

[26]  E. Nord.  The trade-off between severity of illness and treatment effect in cost-value analysis of health care. , 1993, Health policy.

[27]  E. Nord.  The relevance of health state after treatment in prioritising between different patients. , 1993, Journal of medical ethics.

[28]  C E Phelps,et al.  On the (Near) Equivalence of Cost-Effectiveness and Cost-Benefit Analyses , 1991, International Journal of Technology Assessment in Health Care.

[29]  R. Kaplan,et al.  Are large differences in "lifesaving" costs justified? A psychometric study of the relative value placed on preventing deaths. , 1989, Risk analysis : an official publication of the Society for Risk Analysis.

[30]  Cam Donaldson,et al.  The new myth: the social value of the QALY. , 2008, PharmacoEconomics.

[31]  M. Young,et al.  Health services research , 2008, Journal of General Internal Medicine.

[32]  H. Mason.  Monetary valuation of health outcomes for use in national policy formulation. , 2007 .

[33]  J. Richardson,et al.  The significance of age and duration of effect in social evaluation of health care , 2005, Health Care Analysis.

[34]  J. Murray,et al.  The Global Burden of Disease , 1996 .